Neurogene Inc (NGNE)

NASDAQ
Currency in USD
16.410
+0.270(+1.67%)
Real-time Data
NGNE Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
Day's Range
16.16316.640
52 wk Range
13.47074.490
Key Statistics
Edit
Prev. Close
16.14
Open
16.22
Day's Range
16.163-16.64
52 wk Range
13.47-74.49
Volume
12.8K
Average Volume (3m)
232.92K
1-Year Change
-67.36%
Book Value / Share
20.89
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
NGNE Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
50.200
Upside
+205.91%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year
Show more

Neurogene Inc Company Profile

Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company is headquartered in New York, New York.

Neurogene Inc SWOT Analysis


Gene Therapy Promise
Neurogene's NGN-401 shows potential in treating Rett syndrome, a rare neurological disorder, with encouraging safety data and functional activity in preclinical studies
Market Opportunity
Rett syndrome treatment market estimated at $2.5 billion, with Neurogene's NGN-401 positioned for potential 60% market share in a projected duopoly
Financial Landscape
Despite negative EPS forecasts through 2025, Neurogene maintains a healthy cash position. Analysts set a $65 price target, reflecting confidence in future growth
EXACT Platform Edge
Explore Neurogene's EXACT technology, a self-regulatory platform with potential to expand gene therapy applications beyond Rett syndrome to other genetic disorders
Read full SWOT analysis

Compare NGNE to Peers and Sector

Metrics to compare
NGNE
Peers
Sector
Relationship
P/E Ratio
−3.3x−2.2x−0.5x
PEG Ratio
0.01−0.010.00
Price/Book
0.8x1.5x2.6x
Price / LTM Sales
268.6x12.3x3.0x
Upside (Analyst Target)
233.1%320.7%57.1%
Fair Value Upside
Unlock26.9%10.6%Unlock

Analyst Ratings

7 Buy
0 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 50.200
(+205.91% Upside)

Earnings

Latest Release
Nov 14, 2023
EPS / Forecast
-- / -0.03
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

FAQ

What Is the Neurogene (NGNE) Stock Price Today?

The Neurogene stock price today is 16.41

What Stock Exchange Does Neurogene Trade On?

Neurogene is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Neurogene?

The stock symbol for Neurogene is "NGNE."

What Is the Neurogene Market Cap?

As of today, Neurogene market cap is 243.26M.

What is Neurogene Earnings Per Share?

The Neurogene EPS is -4.28.

From a Technical Analysis Perspective, Is NGNE a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.